# ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

> **NCT04049513** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Malaghan Institute of Medical Research** · enrollment: 30 (actual)

## Conditions studied

- Lymphomas Non-Hodgkin's B-Cell
- Diffuse Large B-cell Lymphoma (DLBCL)
- Primary Mediastinal B-cell Lymphoma (PMBCL)
- Transformed Follicular Lymphoma (TFL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)

## Interventions

- **BIOLOGICAL:** WZTL002-1 (1928T2z CAR-T cells)
- **DRUG:** Cyclophosphamide and Fludarabine lymphodepleting chemotherapy

## Key facts

- **NCT ID:** NCT04049513
- **Lead sponsor:** Malaghan Institute of Medical Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-11
- **Primary completion:** 2024-06-12
- **Final completion:** 2029-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04049513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04049513, "ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04049513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*